Glenn Takayama, M.B.A. is currently the CEO and founder of PathCom Systems, a company that designs and manufactures robotic liquid handling equipment and also develops and manufactures reagents used on the equipment. Glenn has also founded, ran and sold two other biotech companies in the Bay Area. He has worked for companies in Telecommunications Electronics, Aerospace, and Computer Electronics before going into the Biotech field. He has experience in M&A, accounting, engineering, manufacturing, materials, sales & marketing and facilities design and construction. Glenn has a BS in Engineering and MBA from the University of California, Berkeley.
Deebie Symmes, M.B.A. is a business development consultant who has over 20 years of experience in business development, licensing, strategic planning, and marketing research across the therapeutics and diagnostics industries. Since May 2015, she has been consulting for Newomics on a part-time basis, providing advice on strategic alliances, partnerships, marketing, licensing, and sales strategies. For the past 6 years, she has been part of the consulting group- Keelin Reeds Partners. She previously served as Senior Director, Business Development at ARYx Therapeutics, Fremont, CA, where she led partnering efforts on several drugs and completed a licensing deal valued at $475 million. Before ARYx she held senior posts in business development at Tularik, MetaXen, and Chiron, leading numerous corporate partnering efforts in central nervous system, cardiology, hematology, and immune-mediated disease therapy areas. She started her career at Arthur D. Little in management consulting, and subsequently spent eight years in diagnostics with Ciba-Corning Diagnostics and then Chiron’s Nucleic Acid Testing Division, during which time she negotiated and led over 50 in-licensing transactions and worked on several M&A projects. She continues to develop expertise across both therapeutic and diagnostic marketplaces, and brings a deep understanding of the drug discovery process. Ms. Symmes received her M.B.A. from the Wharton School, University of Pennsylvania.
Brian Fraser, J.D. is an experienced corporate attorney offering a wide range of cost-effective legal services to both start-up and established companies. He has spent over 27 years providing legal services to various companies, during which time he has acquired extensive expertise in commercial, M&A, licensing and general corporate matters. Since August 2015, he has been consulting for Newomics on a part-time basis. Most of his current practice involves working as “outside general counsel” for companies that given their maturity and/or budget constraints cannot employ full-time in-house counsel. On the start-up side, he typically forms the business entity, prepares all formation documents, and to the extent the start-up is funded by outside angels or VCs, he assists in the negotiation and preparation of all investor financing documents. He also prepares all documents and filings necessary to set up an employee stock option plan. He also has extensive experience in negotiating patent and software license agreements, development agreements, reseller and OEM agreements, and strategic partnering arrangements. He has extensive experience in the area of mergers and acquisitions. Mr. Fraser receives his J.D. from UC Davis, School of Law and B.A. from UCLA. He is also a Certified Public Accountant and holds a Master of Science degree in Finance.